Skip to main content

Table 1 Baseline characteristics of subjects by follow up status

From: Common genetic polymorphisms of microRNA biogenesis pathway genes and breast cancer survival

  Disease-free survival (n = 480) Overall survival (n = 488)
  Relapse (n = 90)a No relapse (n = 389) HR (95% CI) P aHR (95% CI) b P Death (n = 41) Alive (n = 447) HR (95% CI) P aHR (95% CI) c P
Follow up duration, years (median) 0.12-8.34 (4.64)      0.18-9.45 (6.24)     
Age (mean(SD)) 46.3 (12.5) 46.6 (10.6) 0.99 (0.97- 1.01) 0.470 1.00 (0.98- 1.02) 0.918 45.8 (13.8) 46.8 (10.7) 0.98 (0.96- 1.01) 0.289 0.99 (0.97- 1.02) 0.632
Tumor size             
 ≤2 cm  27 (30.0) 210 (55.1) 1 (reference)   1 (reference)   10 (21.7) 229 (52.9) 1 (reference)   1 (reference)  
 >2 cm 63 (70.0) 171 (44.9) 2.49 (1.59- 3.91) <.001 1.66 (1.01- 2.72) 0.045 36 (78.3) 204 (47.1) 3.73 (1.85- 7.52) <.001 2.20 (1.03- 4.67) 0.041
Lymph-node involvement             
 No  36 (40.0) 258 (67.5) 1 (reference)   1 (reference)   15 (32.6) 282 (65.0) 1 (reference)   1 (reference)  
 Yes  54 (60.0) 124 (32.5) 3.00 (1.97- 4.58) <.001 2.54 (1.60- 4.03) <.001 31 (67.4) 152 (35.0) 3.86 (2.08- 7.16) <.001 2.70 (1.40- 5.20) 0.003
Metastasis             
 No  90 (100) 389 (100) - - - - 42 (91.3) 432 (99.1) 1 (reference)   1 (reference)  
 Yes         4 (8.7) 4 (0.9) 7.15 (2.55-20.02) <.001 5.26 (1.71-16.15) 0.004
Histologic grade             
 I-II  23 (30.7) 207 (61.4) 1 (reference)   1 (reference)   12 (31.6) 221 (58.3) 1 (reference)   1 (reference)  
 III  52 (69.3) 130 (38.6) 3.00 (1.84- 4.90) <.001 3.40 (1.74- 6.64) <.001 26 (68.4) 158 (41.7) 2.81 (1.42- 5.56) 0.003 1.93 (0.93- 4.03) 0.078
Nuclear grade             
 I-II  21 (40.4) 146 (59.4) 1 (reference)   1 (reference)   8 (34.8) 160 (57.1) 1 (reference)   1 (reference)  
 III  31 (59.6) 100 (40.7) 1.82 (1.05- 3.17) 0.034 0.59 (0.28- 1.23) 0.161 15 (65.2) 120 (42.9) 2.52 (1.07- 5.94) 0.035 1.12 (0.40- 3.11) 0.830
Estrogen receptor             
 Positive  49 (55.1) 238 (63.0) 1 (reference)   1 (reference)   22 (48.9) 269 (62.9) 1 (reference)   1 (reference)  
 Negative  40 (44.9) 140 (37.0) 1.33 (0.88- 2.03) 0.177 1.69 (0.79- 3.62) 0.177 23 (51.1) 159 (37.2) 1.82 (1.02- 3.28) 0.044 1.02 (0.37- 2.80) 0.975
Progesterone receptor             
 Positive  42 (47.7) 202 (53.6) 1 (reference)   1 (reference)   18 (40.0) 230 (54.0) 1 (reference)   1 (reference)  
 Negative 46 (52.3) 175 (46.4) 1.23 (0.81- 1.87) 0.331 1.53 (0.79- 2.96) 0.202 27 (60.0) 196 (46.0) 1.75 (0.96- 3.18) 0.066 1.14 (0.48- 2.73) 0.765
Adjuvant chemotherapy             
 Yes  78 (88.6) 285 (76.0) 1 (reference)   1 (reference)   41 (91.1) 327 (76.9) 1 (reference)   1 (reference)  
 No  10 (11.4) 90 (24.0) 0.47 (0.24- 0.91) 0.026 1.00 (0.47- 2.14) 0.996 4 (8.9) 98 (23.1) 0.36 (0.13- 1.00) 0.049 1.16 (0.37- 3.60) 0.804
Hormone receptor therapy             
 Yes  47 (52.8) 263 (70.1) 1 (reference)   1 (reference)   21 (46.7) 292 (68.5) 1 (reference)   1 (reference)  
 No  42 (47.0) 112 (29.9) 1.79 (1.18- 2.71) 0.006 2.43 (1.17- 5.07) 0.018 24 (53.3) 134 (31.5) 2.33 (1.30- 4.18) 0.005 1.51 (0.80- 2.85) 0.201
Radiotherapy             
 Yes  43 (48.9) 185 (49.7) 1 (reference)   1 (reference)   20 (43.5) 211 (50.0) 1 (reference)   1 (reference)  
 No  45 (51.1) 187 (50.3) 0.90 (0.59- 1.37) 0.633 0.96 (0.62- 1.48) 0.843 26 (56.5) 211 (50.0) 1.10 (0.61- 1.97) 0.760 1.12 (0.61- 2.04) 0.723
  1. NOTE Column frequency may be less than total number of subjects due to missing values.
  2. a Disease free survival event (relapse) included locoregional recurrence (n=76), 2nd primary cancer (n=11), and death (n=3) from any cause.
  3. b Adjusted for age, tumor size (≤2cm and >2cm), lymph-node involvement (no and yes), histologic grade (I-II and III), nuclear grade (I-II and III) and ER status (positive and negative), PR status (positive and negative) and hormone receptor therapy (yes and no.).
  4. c Adjusted for age, tumor size (≤2cm and >2cm), lymph-node involvement (no and yes), metastasis (no and yes), histologic grade (I-II and III), and hormone receptor therapy (yes and no).